AltMountain

Perceptive Advisors

New York, NY · CRD 154703
Hedge fund manager

Perceptive Advisors is an SEC-registered investment adviser based in New York, NY that reports managing 6 hedge funds on Form ADV. It reports $11.8 billion in regulatory assets under management. Its private funds, of all types, hold $11.7 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +25.8% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +103.5% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$11.8 billionForm ADV Item 5.F
Gross assets of private funds
$11.7 billionAll private fund types, Form ADV
Hedge funds managed
617 private funds in total
Employees
49Form ADV Item 5.A
Registration
SEC-registered adviserCRD 154703
Latest Form ADV
07/13/2026Disciplinary disclosures: yes, see SEC record

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+25.8%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+103.5%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$6.4 billion101 positions, 2026-06-30
$94$149$203Q3 2024Q1 2025Q3 2025Q1 202613F est. $203S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+21.6%+14.8%
Q1 2026+3.5%-4.6%
Q4 2025+28.1%+2.4%
Q3 2025+26.7%+7.8%
Q2 2025+6.1%+10.4%
Q1 2025-11.4%-4.5%
Q4 2024-9.8%+2.1%
Q3 2024+17.5%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

The 50 largest of 99 share positions ($5,328,616,812) reported by Perceptive Advisors LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Praxis Precision Medicines I11.07%
  • Amylyx Pharmaceuticals Inc5.77%
  • Spyre Therapeutics Inc5.48%
  • Celcuity Inc4.75%
  • Rhythm Pharmaceuticals Inc4.53%
  • Roivant Sciences LTD4.47%
  • Relay Therapeutics Inc4.31%
  • Ascendis Pharma A/s4.15%
  • Travere Therapeutics Inc3.91%
  • Freenome Inc3.73%
StockValue% of 13F portfolioSharesShares vs prior quarter
Praxis Precision Medicines I$589,676,97111.07%2,024,781-0.55%
Amylyx Pharmaceuticals Inc$307,695,6895.77%10,573,735+26.86%
Spyre Therapeutics Inc$292,102,3555.48%3,280,943-24.04%
Celcuity Inc$252,857,2194.75%3,179,794-0.54%
Rhythm Pharmaceuticals Inc$241,137,3204.53%2,532,556-2.08%
Roivant Sciences LTD$238,105,8444.47%6,510,961-19.47%
Relay Therapeutics Inc$229,782,5654.31%12,730,336-9.75%
Ascendis Pharma A/s$221,341,6294.15%971,521-16.52%
Travere Therapeutics Inc$208,606,7173.91%3,542,913-5.59%
Freenome Inc$198,545,3343.73%12,606,053New
Edgewise Therapeutics Inc$168,014,2493.15%4,138,282-5.39%
Inhibrx Biosciences Inc$129,349,6972.43%1,292,463-0.41%
Nurix Therapeutics Inc$127,361,3242.39%5,371,629+24.33%
Kardigan Inc$120,959,7642.27%8,200,662Unchanged
Meiragtx Hldgs PLC$118,653,2382.23%10,786,658Unchanged
Protagonist Therapeutics Inc$117,865,6152.21%836,579-14.80%
Immatics N.V$98,744,4101.85%11,246,516+8.31%
Zymeworks Inc$93,920,3211.76%3,545,501-15.24%
Oruka Therapeutics Inc$89,317,1141.68%1,072,363-20.27%
Revolution Medicines Inc$88,898,1061.67%433,100-17.91%
Solid Biosciences Inc$86,085,0501.62%11,906,646Unchanged
Biocryst Pharmaceuticals Inc$85,814,7271.61%10,301,888-0.07%
Avalyn Pharmaceuticals Inc$76,219,1831.43%2,675,296Unchanged
Tango Therapeutics Inc$67,190,3501.26%2,693,000-20.25%
Waters Corp$59,317,6501.11%135,000New
Repligen Corp$52,374,2170.98%272,456+9.77%
Artivion Inc$48,202,4580.90%2,112,290+21.59%
Alto Neuroscience Inc$44,957,0540.84%1,760,950+9.38%
Opus Genetics Inc$43,560,0000.82%9,000,000New
Lakefront Biotherapeutics NV$36,837,2780.69%1,242,404New
Abbott Laboratories$34,118,5870.64%345,225New
Blossomhill Therapeutics Inc$33,779,2780.63%1,812,193New
Orchestra Biomed Hldgs Inc$31,333,9090.59%5,037,606Unchanged
Corvus Pharmaceuticals Inc$28,920,2800.54%2,510,441-5.89%
Anteris Technologies Global$26,615,9490.50%3,425,476Unchanged
Adlai Nortye LTD$26,568,0320.50%1,660,502-7.40%
Minimed Group Inc$25,700,4000.48%1,320,000New
Cytomx Therapeutics Inc.$25,209,1260.47%9,268,061-11.22%
Rapport Therapeutics Inc$24,337,8910.46%724,342-6.34%
Septerna Inc$22,205,4530.42%567,479New
X4 Pharmaceuticals Inc$21,316,4240.40%7,350,491-7.35%
Enliven Therapeutics Inc$21,201,2750.40%462,506New
Sab Biotherapeutics Inc$21,009,1780.39%6,627,501Unchanged
Dyne Therapeutics Inc$20,384,9820.38%1,265,362-52.95%
Evolus Inc$19,674,2800.37%2,459,285Unchanged
Yarrow Bioscience Inc$18,310,9660.34%813,098New
Immunovant Inc$17,543,4740.33%519,345-61.74%
Scribe Therapeutics Inc$16,938,8760.32%920,341New
Nautilus Biotechnology Inc$16,421,9360.31%11,564,744-0.60%
Sutro Biopharma Inc$15,640,3290.29%970,846-25.60%

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 23 new positions, 25 sold out, 11 increased, 40 reduced and 25 unchanged.

Number of positions (a count, not dollars)

  • New positions23
  • Increased11
  • Unchanged25
  • Reduced40
  • Sold out25

New positions

StockValueShares
Freenome Inc$198,545,33412,606,053
Waters Corp$59,317,650135,000
Opus Genetics Inc$43,560,0009,000,000
Lakefront Biotherapeutics NV$36,837,2781,242,404
Abbott Laboratories$34,118,587345,225
Blossomhill Therapeutics Inc$33,779,2781,812,193
Minimed Group Inc$25,700,4001,320,000
Septerna Inc$22,205,453567,479
Enliven Therapeutics Inc$21,201,275462,506
Yarrow Bioscience Inc$18,310,966813,098
Scribe Therapeutics Inc$16,938,876920,341
Grail Inc$13,579,16996,911
Veradermics Inc$11,759,31097,000
Entera Bio LTD$9,985,2933,431,372
Research Alliance Corp IV$8,288,000700,000
Capricor Therapeutics Inc$8,049,500850,000
Damora Therapeutics Inc Com SHS$6,012,111282,524
Adarx Pharmaceuticals Inc$5,982,000300,000
Olema Pharmaceuticals Inc$4,968,000575,000
Ceribell Inc$2,409,22098,779

Sold out

StockValue at Jun 30, 2026Shares held then
Nuvalent Inc$195,192,3681,580,505
Apogee Therapeutics Inc$173,625,8381,308,113
Ionis Pharmaceuticals Inc$44,878,140566,000
Jazz Pharmaceuticals PLC$40,964,900170,000
Sionna Therapeutics Inc$39,810,950905,000
Corcept Therapeutics Inc$34,639,576398,385
Damora Therapeutics Inc$31,810,2301,223,000
Charles Riv Labs Intl Inc$31,750,600140,000
Axsome Therapeutics Inc.$28,993,007118,450
Tenax Therapeutics Inc$24,735,0001,700,000
Intuitive Surgical Inc$20,633,22951,884
Contineum Therapeutics Inc$20,579,1531,255,592
Omada Health Inc$17,259,943786,330
Oscar Health Inc$11,408,000400,000
Boston Scientific Corp$10,670,000250,000
Natera Inc$9,416,32934,689
Research Alliance Corp III$8,025,000750,000
Cullinan Therapeutics Inc$7,766,164426,478
Phathom Pharmaceuticals Inc$5,772,200532,000
Cogent Biosciences Inc$4,685,873121,082

Largest increases

StockChange in sharesChangeValue nowShares now
Amylyx Pharmaceuticals Inc+2,238,853+26.86%$307,695,68910,573,735
Nurix Therapeutics Inc+1,051,207+24.33%$127,361,3245,371,629
Artivion Inc+375,000+21.59%$48,202,4582,112,290
Immatics N.V+863,060+8.31%$98,744,41011,246,516
Crescent Biopharma Inc.+500,000+241.61%$10,314,284706,942
Guardant Health Inc+28,673+69.38%$12,485,20070,000
Repligen Corp+24,244+9.77%$52,374,217272,456
Xeris Biopharma Holdings Inc+466,658+99.92%$8,925,895933,671
Alto Neuroscience Inc+151,057+9.38%$44,957,0541,760,950
Uniqure NV+66,773+19.87%$9,730,996402,773
Axogen Inc+32,688+13.22%$11,737,600280,000

Largest reductions

StockChange in sharesChangeValue nowShares now
Spyre Therapeutics Inc-1,038,553-24.04%$292,102,3553,280,943
Roivant Sciences LTD-1,574,500-19.47%$238,105,8446,510,961
Biogen Inc-248,143-89.85%$6,331,41628,030
Ascendis Pharma A/s-192,200-16.52%$221,341,629971,521
Unitedhealth Group Inc-106,806-91.44%$3,670,80010,000
Immunovant Inc-838,038-61.74%$17,543,474519,345
Relay Therapeutics Inc-1,375,851-9.75%$229,782,56512,730,336
Adaptive Biotechnologies Cor-805,000-66.13%$11,916,193412,325
Dyne Therapeutics Inc-1,423,873-52.95%$20,384,9821,265,362
Oruka Therapeutics Inc-272,700-20.27%$89,317,1141,072,363
Protagonist Therapeutics Inc-145,300-14.80%$117,865,615836,579
Revolution Medicines Inc-94,500-17.91%$88,898,106433,100
Tango Therapeutics Inc-684,000-20.25%$67,190,3502,693,000
Zymeworks Inc-637,452-15.24%$93,920,3213,545,501
Nuvectis Pharma Inc-760,000-76.00%$5,068,800240,000
Danaher Corp Del-70,000-53.85%$13,293,00060,000
Irhythm Holdings Inc-110,000-49.16%$12,930,644113,766
Travere Therapeutics Inc-209,661-5.59%$208,606,7173,542,913
Edgewise Therapeutics Inc-235,692-5.39%$168,014,2494,138,282
DBV Technologies S A-516,816-31.26%$13,365,6401,136,534

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Yarrow Bioscience, Inc.13G amendment9.99%1,600,647Nov 16, 2026SEC.gov ↗
Sutro Biopharma, Inc.13G amendment5.8%970,846Nov 16, 2026SEC.gov ↗
Research Alliance Corporation IV13G amendment9%700,000Nov 16, 2026SEC.gov ↗
Research Alliance Corporation III13G amendment0%0Nov 16, 2026SEC.gov ↗
Orchestra BioMed Holdings, Inc.13G amendment8.15%6,537,606Nov 16, 2026SEC.gov ↗
Nurix Therapeutics, Inc.13G amendment4.9%5,371,629Nov 16, 2026SEC.gov ↗
Invivyd, Inc.13G amendment4.7%13,762,637Nov 16, 2026SEC.gov ↗
Opus Genetics, Inc.13G amendment9.99%10,086,525Nov 16, 2026SEC.gov ↗
Freenome, Inc.13G amendment11.3%12,606,053Nov 16, 2026SEC.gov ↗
enGene Therapeutics Inc.13G amendment8.9%6,217,464Nov 16, 2026SEC.gov ↗
Edesa Biotech, Inc.13G amendment4.2%563,239Nov 16, 2026SEC.gov ↗
Amylyx Pharmaceuticals, Inc.13G amendment8.2%10,573,735Nov 16, 2026SEC.gov ↗
Adagio Medical Holdings, Inc.13G amendment44.4%523,356Nov 16, 2026SEC.gov ↗
Trinity Biotech plc13D amendment9.99%54,148,590Nov 10, 2026SEC.gov ↗
Nautilus Biotechnology, Inc.13D amendment3.9%4,944,512Nov 3, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 14, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 50 companies. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (3)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private equity funds filing Form D (5)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (20)

Fund
Gross assets
Minimum
Owners
Adviser
Perceptive Life Sciences Master Fund, LTD
Cayman IslandsHedge fund
Gross assets$5.6B
Minimum$1.0M
Owners400
AdviserPerceptive Advisors
Perceptive Credit Opportunities Fund IV, LP
Delaware, United StatesHedge fund
Gross assets$1.4B
Minimum$5.0M
Owners285
AdviserPerceptive Advisors
Perceptive Credit Opportunities Fund III, LP
Delaware, United StatesHedge fund
Gross assets$1.1B
Minimum$5.0M
Owners151
AdviserPerceptive Advisors
Perceptive Credit Opportunities Fund II, LP
Delaware, United StatesHedge fund
Gross assets$540M
Minimum$5.0M
Owners123
AdviserPerceptive Advisors
Perceptive Xontogeny Venture Fund II, LP
Delaware, United StatesVenture capital fund
Gross assets$508M
Minimum$500K
Owners181
AdviserPerceptive Advisors
Pcof Phoenix II Fund, LP
Delaware, United StatesHedge fund
Gross assets$207M
Minimum$5.0M
Owners4
AdviserPerceptive Advisors
Perceptive Xontogeny Venture Fund, LP
Delaware, United StatesVenture capital fund
Gross assets$179M
Minimum$500K
Owners134
AdviserPerceptive Advisors
LEV Lb Holdings, LP
Delaware, United StatesPrivate equity fund
Gross assets$97.8M
MinimumNone set
Owners37
AdviserPerceptive Advisors
Pcof Eq Aiv III, LP
Delaware, United StatesPrivate fund
Gross assets$7.0M
MinimumNone set
Owners101
AdviserPerceptive Advisors
Perceptive Ls (A), LLC
Delaware, United StatesPrivate equity fund
Gross assets$6.8M
MinimumNone set
Owners5
AdviserPerceptive Advisors
Pcof Eq Aiv II, LP
Delaware, United StatesPrivate fund
Gross assets$4.0M
MinimumNone set
Owners48
AdviserPerceptive Advisors
PX Venture (C), LLC
Delaware, United StatesPrivate equity fund
Gross assets$3.9M
MinimumNone set
Owners1
AdviserPerceptive Advisors
Perceptive SP (C), LP
Delaware, United StatesPrivate equity fund
Gross assets$3.9M
MinimumNone set
Owners5
AdviserPerceptive Advisors
PX Venture (A), LLC
Delaware, United StatesPrivate equity fund
Gross assets$2.1M
MinimumNone set
Owners5
AdviserPerceptive Advisors
PX Venture (B), LLC
Delaware, United StatesPrivate equity fund
Gross assets$416K
MinimumNone set
Owners15
AdviserPerceptive Advisors
Perceptive SP (E), LP
Delaware, United StatesPrivate equity fund
Gross assets$8K
MinimumNone set
Owners1
AdviserPerceptive Advisors
Perceptive Discovery Fund a LP
Delaware, United StatesPrivate equity fund
Gross assets$0
Minimum$1.0M
Owners0
AdviserPerceptive Advisors
Pcof Eq Aiv IV, LP
Delaware, United StatesPrivate fund
Gross assets$0
MinimumNone set
Owners118
AdviserPerceptive Advisors
Perceptive Discovery Fund LP
Delaware, United StatesPrivate equity fund
Gross assets$0
Minimum$1.0M
Owners0
AdviserPerceptive Advisors
Pcof Phoenix II Aiv III, LP
Delaware, United StatesPrivate fund
Gross assets$0
MinimumNone set
Owners1
AdviserPerceptive Advisors

As reported in the adviser's Form ADV filed Aug 8, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​‌​⁠